Loading clinical trials...
Loading clinical trials...
FIRE-HFpEF is a multi-center, prospective, randomized, single-blinded, clinical feasibility study. This study will enroll up to 105 subjects with heart failure with preserved ejection fraction in the United States. Data will be collected to evaluate whether pacing therapies can lead to improvements in exercise capacity and health status of subjects.
After enrollment, baseline data will be collected, and subjects will then have a pacemaker implanted. After 6 weeks, subjects will have a follow up visit with a blood draw and a cardiac MRI. At this visit, subjects will be randomized 2:1 for pacing therapy or as a control (programmed into either a non-pacing mode or an exertional rate-adaptive pacing mode with no planned pacing at rest). After 3, 6 and 9 months after randomization, subjects will return for a follow up visit. At the 9-month visit therapy modifications will be made based on initial pacing randomization assignment: pacing therapy will be terminated in the original therapy group and enabled in the control group. After an additional 3-months of follow-up, subjects will return for their final visit, therapies will be disabled in all subjects and subjects will be exited. Echocardiographic, functional, and health status endpoints will be collected and analyzed to assess therapy efficacy.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
NCH Heart Institute
Naples, Florida, United States
Prairie Education and Research Cooperative-St. Elizabeth's
O'Fallon, Illinois, United States
Prairie Education and Research Cooperative-St. John's
Springfield, Illinois, United States
University of Kansas Medical Center
Kansas City, Kansas, United States
Duke University
Durham, North Carolina, United States
Oklahoma Heart Hospital
Oklahoma City, Oklahoma, United States
Dallas VA Medical Center
Dallas, Texas, United States
Houston Methodist Research Institute
Houston, Texas, United States
The University of Vermont Medical Center
Burlington, Vermont, United States
Start Date
September 11, 2024
Primary Completion Date
July 1, 2026
Completion Date
July 1, 2027
Last Updated
January 27, 2026
105
ESTIMATED participants
Pacemaker PLR + TRT ON
DEVICE
Pacemaker non-pacing mode or an exertional rate-adaptive pacing mode with no planned pacing at rest.
DEVICE
Lead Sponsor
Medtronic Cardiac Rhythm and Heart Failure
NCT07057466
NCT07093528
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions